Intestinal parasitic infections and leishmaniasis in HIV infected patients;Infecciones parasitarias intestinales y leishmaniosis en pacientes con infeccion por el VIH

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 16, Issue SUPPL. 1, 1998, Pages 52-60

  Moreno Camacho, Asunción ^a   López Vélez, Rogelio ^b   Muñoz Sanz, Agustín ^c   Labarga Echevarría, Pablo ^d  

^a HOSPITAL CLÍNIC   (Spain)

^b HOSPITAL RAMÓN Y CAJAL   (Spain)

^c HOSPITAL INFANTA CRISTINA   (Spain)

^d HOSPITAL SAN PEDRO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALBENDAZOLE; ALLOPURINOL; AMINOQUINOLINE DERIVATIVE; AMPHOTERICIN B; ANTIMONY; ATOVAQUONE; AZITHROMYCIN; COTRIMOXAZOLE; EFLORNITHINE; FUMAGILLIN; GAMMA INTERFERON; KETOCONAZOLE; LETRAZURIL; MEGLUMINE ANTIMONATE; METRONIDAZOLE; PAROMOMYCIN; SITAMAQUINE; SPIRAMYCIN;

ASPIRATION BIOPSY; CRYPTOSPORIDIUM PARVUM; CYCLOSPORA CAYETANENSIS; DRUG EFFICACY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; IMMUNOCOMPETENCE; INTESTINE BIOPSY; INTESTINE INFECTION; INTRAVENOUS DRUG ADMINISTRATION; LEISHMANIASIS; MICROSPORUM; MORTALITY; ORAL DRUG ADMINISTRATION; REVIEW; SPECIES DIFFERENCE;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANIMALS; ANTI-HIV AGENTS; ANTIPROTOZOAL AGENTS; CRYPTOSPORIDIOSIS; DRUG INTERACTIONS; HUMANS; INCIDENCE; INTESTINAL DISEASES, PARASITIC; LEISHMANIA INFANTUM; LEISHMANIASIS; LEISHMANIASIS, VISCERAL; TREATMENT FAILURE;

EID: 0031796355     PISSN: 0213005X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (139)

1. Ehrenpreis DE, Patterson BK, Brainer JA, Yokoo Rademaker AW, Glogowski W et al. Histopathologic findings of duodenal biopsy specimens in HIV-infected patients with and without diarrhea and malabsorption. Am J Clin Pathol 1992; 97: 21-28.
2. Moreno Camacho A, Moreno Martínez A, Valls ME, Bordas JM, Piqué JM, Bombí JA et al. Enteropatía crónica de etiología desconocida en pacientes con sida. Análisis de 40 casos. Med Clin (Barc), 1997; 109: 452-456.
3. Desportes I, Le Charpentier Y, Galian A, Bernard F, Cochand-Priollet B, Lavergne A et al. Occurrence of a new microsporidian: Enterocytozoon bieneusi n.g., n.sp., in the enterocytes of a human patient with AIDS. J Protozool 1985; 32: 250-254.
4. Rotterdam H, Tsang P. Gastrointestinal disease in the immunocompromised patient. Hum Pathol 1994; 25: 1.123-1.140.
5. a ed). Nueva York: Churchill Livingstone, 1995; 2.513-2.524.
6. Cali A, Kotler DP, Orenstein JM. Septata intestinalis n.g., n.sp., an intestinal microsporidian associated with chronic diarrhea and dissemination in AIDS patients. J Eukaryot Microbiol 1993; 40: 101-112.
7. Sobottka I, Schwartz DA, Schottelius J, Visvesvara GS, Pieniazek NJ, Schetz C et al. Prevalence and clinical significance of intestinal microsporidiosis in human immunodeficiency virus-infected patients with and without diarrhea in Germany: A prospective coprodiagnostic study. Clin Infect Dis 1998; 26: 475-480.
8. th International Conference on AIDS, 1993.
9. Rabeneck LI, Gyorkey F, Genta RM, Gyorkey P, Foote LW, Risser JMH. The role of microsporidia in the pathogenesis of HIV-related chronic diarrhea. Ann Intern Med, 1993; 119: 895-899.
10. Orenstein JMI, Dieterich DT, Lew EA, Kotler DP. Albendazole as a treatment for intestinal and disseminated microsporidiosis due to Septata intestinalis in AIDS patients: a report of four patients. AIDS 1993; 7 (Sup, 3): 40-42.
11. Kotler DP, Orenstein JM. Microsporidia and AIDS-associated diarrhea. Clin Infect Dis 1996; 22: 603-604.
12. Lambl BB, Federman M, Pleskow D, Wanke CA. Malabsorption and wasting in AIDS patients with microsporidia and pathogen-negative diarrhea. AIDS 1996; 10: 739-744.
13. López-Vélez RJ, Tarazona R, García Camacho A, Gómez-Mampaso E, Guerrero A, Moreiro V et al. Intestinal and extraintestinal cryptosporidiosis in AIDS patients. Eur J Clin Microbiol Infect Dis, 1995; 14: 677-681.
14. McKenzie WR, Hoxie NJ, Proctor ME, Gradus MS, Blair KA, Peterson DE et al. A massive outbreak in Milwaukee of Cryptosporidium infection transmitted through the public water supply. N Engl J Med 1995; 331: 161-167.
15. Pozio E, Rezza G, Boschini A, Pezzotti P, Tamburini A, Rossi et al. Clinical cryptosporidiosis and human immunodeficiency virus (HIV)-induced immunosuppression: findings from a longitudinal study of HIV-positive and HIV-negative former injection drug users. J Infect Dis 1997; 176: 969-975.
16. Goldstein ST, Juranek DD, Ravenholt O, Hightower AW, Martin DG, Mesnik JL et al. Cryptosporidiosis: an outbreak associated with drinking water despite sataeof-the-art water treatment. Ann Intern Med 1996; 124: 459-468.
17. Ashford RW. Occurrence of an undescribed coccidian in man in Papua New Guinea. Ann Trop Med Parasitol 1979; 73: 497-500.
18. Pollok RCG, Bendall RP, Moody A, Chiodini PL, Churchill DR. Traveler's diarrhoea associated with Cyanobacterium-like bodies. Lancet; 1992; 340: 556-557.
19. Wutz RM, Kocka FE, Peters CS, Weldon-Linne CM, Kuritza A, Yungbluth P et al. Clinical characteristics of seven cases of diarrhea associated with a novel acid-fast organism in the stool. Clin Infect Dis 1993; 16: 136-138.
20. Ortega YRI, Sterling CR, Gilman RH, Cama VA, Díaz F. Cyclospora species: a new protozoan pathogen of humans. N Engl J Med. 1993; 328: 1.308-1.312.
21. Ooi WW, Zimmerman SKI, Needham CA. Cyclospora species: a gastrointestinal pathogen in immunocompetent hosts. J Clin Microbiol 1995; 33: 1.267-1.269.
22. Clarke SCI, McIntyre M. The incidence of Cyclospora cayentanensis stool samples submitted to adistric general hospital. Epidemiol Infect (England), 1996; 117: 189-193.
23. Pape JW, Verdier IR, Boncy M, Boncy J, Jonson WD Jr. Cyclospora infection in adults infected with HIV. Clinical manifestations, treatment and prophylaxis. Ann Intern Med 1994; 121: 654-657.
24. Centers for Disease Control and Prevention. Update: outbreaks of Cyclospora cayetanensis infection-United States and Canada, 1996. MMWR, 1996; 45: 611-612.
25. Huang P, Weber JT, Sosin DM, Griffin PM, Long EG, Murphy JJ. The first reported outbreak of diarrheal illness associated with Cyclospora in the United States. Ann Intern Med, 1995; 123: 409-414.
26. Soave P, Johnson W Jr. Cyptosporidium and isospora bacili infection, AIDS commentary. J Infect Dis 1988; 157: 225-229.
27. Dellovitz JA, Pape JW, Boncy M, Johnson WD Jr. Clinical manifestations and therapy of Isospora belli infection in patients with the acquired immunodeficiency syndrome. N Engl J Med 1986; 315: 87-90.
28. Karasik MS, Afdhal NH. Small and large bowel infections in AIDS. En: LaMont JT, editor. Gastrointestinal infections. Nueva York: Marcel Dekker, Inc., 1997; 191-245.
29. Orenstein JM, Chiang J, Steinberg W, Smith PD, Rotterdam H, Kotler DP. Intestinal microsporidiosis as a cause of diarrhea in human immunodeficiency virus-infected patiens: a report of 20 patients. Hum Pathol 1990; 21: 475-481.
30. Rijpstra AC, Canning EU, Van Ketel RJ, Eeftinck-Schattenkerk JK, Laarman JJ. Use of light microscopy to diagnose small intestinal microsporidiosis in patients with AIDS. J Infect Dis, 1988; 157: 827-831.
31. Schwartz DA, Bryan RT, Weber, Visvesvara GS. Microsporidiosis in HIV positive patients: current methods for diagnosis using biopsy, cytologic, ultrastructural, immunological and tissue culture techniques. Folia Parasitol 1994; 41: 101-109.
32. Weber R, Bryan RT, Owen RL, Wilcox CM, Gorelkin L, Visvesvara GS. Improved light-microscopical detection of microsporidia spores in stool and duodenal aspirates. N Engl J Med 1992; 326: 161-166.
33. Ryan NJ, Sutherland G, Coughlan KJ, Globan M, Doultree J, Marshall J et al. A new trichrome-blue stain for detection of microsporidial species in urine, stool, and nasopharyngeal specimens. J Clin Microbiol, 1993; 31: 3.264-3.269.
34. Kokoskin E, Gyorkos TW, Camus A, Cedilotte L, Purtill T, Ward B. Modified technique for efficient detection of microsporidia. J Clin Microbiol 1994; 32:1.074-1.075.
35. Didier ESI, Orenstein JM, Aldras A, Bertucci D, Rogers LB, Janney FA. Comparison of three staining methods for detecting microsporidia in fluids. J Clin Microbiol 1995; 33: 3.138-3.145,
36. Van Gool T, Sniijders F, Reiss P, Eeftinck Schattenberg JKM, Van den Bergh Weerman MA, Bartelsman JFWM et al. Diagnosis of intestinal and disseminated microsporidial infections in patients with HIV by a new rapid fluorescence technique. J Clin Pathol 1993; 46: 694-699.
37. Fedorko DPI, Nelson NA, Catwright CP. Identification of microsporidia in stool specimens by using PCR and restriction endonucleases. J Clin Microbiol 1995; 33: 1.739-1.741.
38. Henricksen SA, Pohlenz JFL. Staining of cryptosporidia by a modified Ziehl-Neelsen technique. Acta Vet Scand 1981; 22: 594-596.
39. Baxby D, Blundell N. Sensitive, rapid, simple methods for detecting. Cryptosporidium in faeces [carta]. Lancet 1983; 2: 1.149.
40. Bronsdon MA. Rapid dimethyl sulfoxide-modified acid-fast stain of Cryptosporidium oocysts in stool specimens. J Clin Microbiol 1984; 19: 952-953.
41. Ritchie LS, Pan C, Hunter GW. A comparison of the zincsulfate and the MGL (formalin-ether) techniques. J Parasitol, 1952; 38: 16.
42. Sheather AL. The detection of intestinal protozoa and mange parasites by flotation technique. J Comp Pathol, 1953; 36: 268-275.
43. Mintz DE, Long EG. CLB: an emerging infectious cause of chronic diarrhea. Infect Dis, Clin Pract, 1995; 3: 315-320.
44. Dytrych JK, Cooke RPD. Autofluorescence of Cyclospora. Br J Biomed Sci, 1995; 52: 76.
45. Connor BA, Shlim DR, Scholes JV, Rayburn JL, Reidy J, Rajah R. Pathologic changes in the small bowel in nine patients with diarrhea associated with a coccidia-like body. Ann Intern Med, 1.993; 119: 377-382.
46. Sun T, Ilardi CF, Asnis D, Bresciani AR, Goldenberg S, Roberts B et al. Light and electron microscopic identification of Cyclospora species in the small intestine. Am J Clin Pathol 1996; 105: 216-220.
47. Long EG, White EH, Carmichael WW, Quinlisk PM, Raja R, Swisher BL et al. Morphologic and staining characteristics of a Cyanobacterium-like organism associated with diarrhea. J Infect Dis 1991; 164: 199-202.
48. Whiteside ME, Barkin JS, May RG, Weiss SD, Fischl MA, MacLeod CL. Enteric coccidiosis among patients with the acquired immunodeficiency syndrome. Am J Trop Med Hyg 1984; 33: 1.065-1.072.
49. Goodgame RW. Understanding intestinal spore-forming protozoa: cryptosporidia, Isospora and Cyclospora. Ann Intern Med 1996; 124: 429-441.
50. Anwar-Bruni DM, Hogan SE, Schwartz DA, Wilcox CM, Bryan RT, Lennox JL. Atovaquone is effective treatment for the symtoms of gastrointestinal microsporidiosis in HIV-I -infected patients. AIDS 1996; 10: 619-623.
51. Molina JM, Goguel J, Sarfati C, Chastang C, Desportes-Livage I, Michiels JF et al. Potential efficacy of fumagillin in intestinal microsporidiosis due to Enterocytozoon bieneusi in patients with HIV infection: results of a drug screening study. AIDS 1997; 11: 1.603-1.610.
52. Foudraine NA, Weverling GJ, Van Gool T, Roos MTL, Wolf F, Koopmans PP et al. Improvement of chronic diarrhoea in patients with advanced HIV-1 infection during potent antiretroviral therapy. AIDS 1998; 12: 35-41.
53. Carr A, Marriott D, Field A, Vasak E, Cooper DA. Treatment of HIV-1-associated microsporidiosis and cryptosporidiosis with combination anteretroviral therapy. Lancet 1998; 351: 256-261.
54. Goguel J, Katlama C, Sarfati C, Maslo C, Leport C, Molina JM. Remission of AIDS-associated intestinal microsporidiosis with highly active antiretroviral therapy. AIDS 1997; 11: 1.658-1.659.
55. Albrecht H, Sobotka I, Stellbrink HJ, Greten H. Itraconazole in vivo unwirksam gegen Enterocytozoon bieneusi. Arzheim-Forsch 1994; 9: 610.
56. Clezy K, Gold J, Blaze J.L, Jones P. Paramomycin for the treatment of cryptosporidial diarrhoea in AIDS patients. AIDS 1991; 5: 1.146-1.147.
57. Fichtenbaum CJI, Ritchie DJ, Powderly WG. Use of paromomycin for treatment of cryptosporidiosis in patients with AIDS. CID 1993; 16: 298-300.
58. Bissuel F, Cotte L, Rabodonirina M, Rougier P, Piens M, Trepo C. Paromomycin: an effective treatment for cryptosporidial diarrhea in patients with AIDS. Clin Infect Dis 1994; 18: 447-449.
59. White ACJ, Chappell CL, Hayat CS, Kimball KT, Flanigan TP, Goodgame RW. Paromomycin for cryptosporidiosis in AIDS: a prospective, double-blind trial. J Infect Dis 1994; 170: 419-424.
60. Hoepelman MI. Human cryptosporidiosis. Intern J STD-AIDS 1996; 7 (Supl 1): 28-33.
61. Mannheimer SB, Soave R. Protozoal infections in patients with AIDS. Cryptosporidiosis, isosporiasis, cyclosporiasis, and microsporidiosis. Infect Dis Clin North Am, 1994; 8: 483-498.
62. Rehg JE. Activity of azithromycin againts cryptosporidia in immunosuppressed Rats. J Infect Dis 1991; 163: 1.293-1.296.
63. Harris M, Deutsch G, McLean D, Tsoukas CM. A phase I study of letrazuril in AIDS-related cryptosporidiosis. AIDS 1994; 8: 1.109-1.113.
64. Hamour AA, Bonnington A, Hawthorne B, Wilkins GL. Successful treatment of AIDS-related cryptosporidial sclerosing cholangitis. AIDS, 1993; 7: 1.449-1.451.
65. Romeu J, Miró JM, Sirera C, Mallolas J, Arnal J, Valls ME. Efficacy of octreotide in the management of chronic diarrhea in AIDS. AIDS 1991; 5, 1.495-1.499.
66. Montaner JSG, Harris AG, and the Oxctreotide International Multicentre AIDS-Diarrhea Study Group. Octreotide therapy in AIDS-related, refractory diarrhea: results of a multicentre Canadian-European study. AIDS 1995; 9: 209-210.
67. USPHS/IDSA Prevention of Opportunistic Infections Working Group. USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. Ann Intern Med 1997; 127: 922-946.
68. USPHS/IDSA Guidelines for the prevention of opportunistic infections in persons infected with the human immunodeficiency virus. MMWR 1995; 40: RR-8.
69. Holmberg SD, Moorman AC, Von Bargen JC, Palella FJ, Loveless MO, Ward DJ et al. Possible efectiveness of clarithromycin and rifabutin for cryptosporidiosis chemoprophylaxis in HIV disease. JAMA 1998; 279: 384-386.
70. Greenberg RE, Mir R, Bank S, Siegal FP. Resolution of intestinal cryptosporidiosis after treatment of AIDS with AZT. Gastroenterology 1989; 97: 1.327-1.330.
71. Weiss LM, Oerlman DI, Sherman J, Tanowitz H, Wittner M. Isospora belli infection: treatment with pirimethamine. Ann Intern Med 1988; 109: 474-475.
72. Forthal DN, Guest SS. Isospora belli enteritis in three homosexual men. Am J Trop Med Hyg 1984; 33: 1.060-1.064.
73. Musey KL, Chidiac C, Beaucaire G, Houriez S, Fourrier A. Effectiveness of roxithromycin for treating Isospora belli infection. J Infect Dis 1988; 158: 646.
74. Gradoni L, Scalone AI Gramiccia M, Troinai M. Epidemiological surveillance of leishmaniasis in HIV-1-infected individuals in Italy. AIDS, 1996; 10: 785-791.
75. Berman JD. Human leishmaniasis: clinical, diagnostic and chemotherapeutic devepolments in the last 10 years. Clin Infect Dis 1997; 24: 684-703.
76. Laguna F, García-Samaniego J, Soriano V, Valencia E, Redondo C, Alonso MJ et al. Gastrointestinal leishmaniasis in human immunodeficiency virus-infected patients: report of five cases and review. Clin Infect Dis 1994; 19: 48-53.
77. Alvar J, Gutiérrez-Solar B, Molina R, López-Vélez R, García-Camacho A, Martínez P et al. Prevalence of Leishmania infection among AIDS patients. Lancet 1992; 339: 1.427.
78. Alvar J, Cañavate C, Gutiérrez-Solar B, Jiménez M, Laguna F, Lopéz-Vélez R et al. Leishmania and human immunodeficiency virus coinfection: the first 10 years. Clin Microbiol Rev 1997; 10: 298-319.
79. Jiménez MI, Laguna F, De la Torre J, Solis F, Alvar J. New Leismania infantum zymodemes responsible for visceral leishmaniasis in HIV-positive co-infected patients from Spain. Trans R Soc Trop Med Hyg, 1995; 89: 33.
80. Montalbán C, Calleja JL, Erice A, Laguna F, Clotet B, Podzamczer D et al. Visceral leishmaniasis in patients infected with human immunodeficiency virus. J Infect 1990; 21: 261-270.
81. Altes JA, Salas M, Riera M, Udina A, Galmés J, Balanzat J et al. Visceral leishmaniasis: another HIV-associated opportunistic infection? Report of eight cases and review of the literature. AIDS 1991; 5: 201-207.
82. Rosenthal E, Marty P, Poizot-Martin I, Teynes J, Pratlong F, Lafeuillade A et al. Visceral leishmaniasis and HIV-I co-infection in southern France. Trans R Soc Trop Med Hyg 1995; 89: 159-162.
83. Tata M, Kumar A, Feiner H. Visceral leishmaniasis in the acquired immunodeficiency syndrome: report of two cases. Hum Pathol 1993; 24: 1.379-1.381.
84. Montalbán C, Martínez-Fernández R, Calleja JL, García-Díaz JD, Rubio R, Dronda F et al. Visceral leishmaniasis (kala-azar) as an opportunistic infection in patients infected with the human immunodeficiency virus in Spain. Rev Infect Dis, 1989; 11: 655-660.
85. Bissuel F, Leport C, Perronne C, Longuet P, Vilde JL. Fever of unknown origin in HIV-infected patients: a critical analysis of a retrospective series of 57 cases. J Intern Med 1994; 236: 529-535.
86. Miralles P, Moreno S, Pérez-Tascón M, Cosín J, Díaz MD, Bouza E. Fever of uncertain origin in patients infected with the human, immunodeficiency virus. Clin Infect Dis, 1995; 20: 872-875.
87. Laguna F, Adrados M, Alvar J, Soriano V, Valencia ME, Moreno V et al. Visceral leishmaniasis in patients infected with the human immunodeficiency virus. Eur J Clin Microbiol Infect Dis 1997; 16: 898-903.
88. Berenguer J, Moreno S, Cercenado E, Bernaldo de Quirós JCL, García de la Fuente A, Bouza E. Visceral leishmaniasis in patients infected with human immunodeficiency virus (HIV). Ann Intern Med, 1989; 111: 129-132.
89. Dedet JP, Lamber M, Pratlong F. Leishmanioses et infection par le virus de l'immunodéficience humaine. Presse Med 1995, 24: 1.036-1.040.
90. Berbe N, Hailu A, Wolday D, Negesse Y, Cenini P, Frommel D. Ethiopian visceral leishmaniasis patients co-infected with human immunodeficiency virus. Trans R Soc Trop Med Hyg 1995; 89:205-207.
91. Ribera E, Cucurrull E, Ocaña I, Vallespí T, Gasser, Juste C. Leishmaniasis visceral en pacientes con infección por HIV. Enferm Infec Microbiol Clin 1995; 13: 73-79.
92. López-Vélez R, Pérez-Molina JA, Turrientes C), San Miguel L, Guerrero A. Manifestaciones clínicas y factores pronósticos de la leishmaniasis visceral en pacientes HIV + [resumen 14/181. VII Congreso de la Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica, Torremolinos, Málaga: 1996.
93. Roig P, Cuadrado JM, Benítez C, Mayol MJ, López M, Navarro V et al. Leishmaniasis visceral de localización intestinal en pacientes con infección por el virus de la inmunodeficiencia humana: presentación de dos casos. Rev Clin Esp 1993; 192: 271-273.
94. Duarte MIS, Da Mata VLR, Corbbett CEP, Laurenti MD, Chebabo R, Goto H. Interstitial neumonitis in human visceral leishmaniasis. AIDS 1992; 6: 238-240.
95. Pialoux G, Hennequin C, Dupont B, Ravisse P. Cutaneous leishmaniasis in an AIDS patient: cure with itraconazole. J Infect Dis 1990; 162: 1.221-1222.
96. World Health Organization. Report on the consultative meeting on Leishmania/HIV co-infection. WHO/LEISH/95,35p. 1-1 4. Ginebra, Suiza: World Health Organization, 1995.
97. López-Vélez RI, Pérez-Molina J, Guerrero A, Baquero F, Villarrubia J, Escribano L et al. Clinicoepidemiologic characteristics, pronostic factors and survival analysis of patients coinfected with human immunodeficiency virus and Leishmania in an area of Madrid, Spain. Am J Trop Med Hyg 1998; 58: 436-443.
98. Alvar J. Leishmaniasis and AIDS co-infection, the Spanish example. Parasitol Today 1994; 10: 160-163.
99. Dereure J, Reines J, Pratlong F, Lamaury I, Rioux JA, Jambon F et al. Visceral leishmaniasis in HIV-infected patients in the south of France. Bull WHO 1995; 73: 245-246.
100. Martínez P, De la Vega E, Laguna F, Soriano V, Puente S, Moreno V et al. Diagnosis of visceral leishmaniasis in HIV-infected individuals using peripheral blood smears. AIDS 1993; 7: 227-230.
101. López-Vélez R, Laguna F, Alvar J, Pérez-Molina JA, Molina R, Martínez P et al. Parasitic culture of buffy coat for diagnosis of visceral leishmaniasis in human immunodeficiency virus-infected patients. J Clin Microbiol 1995; 33: 937-939.
102. Rajendran P, Chatterjee SN, Gupta JBO. Observations on human bonemarrow for Leishmania donovani. Indian J Pathol Microbiol 1989; 32: 282-285.
103. Siddig M, Ghalib H, Shillington DC, Petersen EA. Visceral leishmaniasis in the Sudan: comparative methods of diagnosis. Trans R Soc Trop Med Hyg 1988; 82: 66-68.
104. Zijlstra EE, Siddig Ali M, El-Hassan AM, El-Toum IA, Satti M, Ghalib HW et al. Kala-azar a comparative study of parasitological methods and the direct agglutination test in diagnosis. Trans R Soc Trop Med Hyg 1992; 86: 505-507.
105. El-Safi SH, Peters W, Evans DA. Studies on the leishmaniasis in the Sudan, 3. Clinical and parasitological studies on visceral and mucosal leishmaniasis. Trans R Soc Trop Med Hyg 1991; 854: 465-470.
106. Molina R, Cañavate C, Cercenado E, Laguna F, López-Vélez R, Alvar J. Indirect xenodiagnosis of visceral leishmaniasis in ten patients with HIV-infection using colonized Phlebotomus perniciosus. AIDS 1994; 8: 277-279.
107. Gradoni L, Scalone AI Gramiccia M. HIV-Leishmania co-infections in Italy: serological data as indication of the sequence of acquisition of the two infections. Trans R Soc Trop Med Hyg 1991; 85: 370-371.
108. Piarroux R, Gambarelli F, Dumon H, Fontes M, Dunan S, Mary C et al. Comparision of PCR with direct examination of bone marrow aspiration, myeloculture and serology for diagnosis of visceral leishmaniasis in immunocompromised patients. J Clin Microbiol 1994; 32: 746-749.
109. Mary C, Lamouroux D, Dunan S, Quilici M. Western blot analysis of anti-bodies to Leishmania infantum antigens: potential of the 14-kD and 16-kD antigens for diagnosis and epidemiologic purposes. Am J Trop Med Hyg 1992; 47: 761-771.
110. Herwaldt BL, Herman JD. Recommendations for treating leishmaniasis with sodium stibogluconate (Pentostam) and review of pertinent clinical studies. Am J Trop Med Hyg 1992; 46: 296-306.
111. Dellamonica P, Bernard E, Le Fichoux Y, Politano S, Carles M, Durand J et al. Allopurinol for treatment of visceral leishmaniasis in patients with AIDS. J Infect Dis 1989; 160: 904-905.
112. Medrano F, Hernández-Quero J, Jiménez E, Pineda JA, Rivero A, Sánchez-Quijano A et al. Visceral leishmaniasis in HIV-infected individuals: a common oportunistic infection in Spain? AIDS 1992; 6: 1.499-1.503.
113. Torre-Cisneros J, Villanueva JL, Kindelán JM, Jurado R, Sánchez-Guijo P. Succesful treatment of antimony-resistant visceral leishmaniasis with liposomal amphotericin B in patients infected with human immunodeficiency virus. Clin Infect Dis 1993; 17: 625-627.
114. Gérgolas M, Castrillo JM, Fernández-Guerrero ML. Visceral leishmaniasis in patients with AIDS: report of three cases treated with pentavelent antimony and interferon-γ. Clin Infect Dis 1994; 17: 56-58.
115. Jha TK. Evaluation of allopurinol in the treatment of kala-azar acurring in North Bihar India. Trans R Soc Trop Med Hyg 1983; 77: 204-207.
116. Kager PA, Rees PH, Wellde BT, Hockmeyer WT, Lyerly WH. Allopurinol in the treatment of visceral leishmaniasis. Trans R Soc Trop Med Hyg 1981; 75: 556-559
117. Laguna F, López-Vélez R, Soriano V, Montilla P, Alvar J, González-Lahoz JM. Assessment of allopurinol plus meglumine antimoniate in the treatment of visceral leishmaniasis in patients infected with HIV. J Infect 1994; 28: 255-259.
118. Mora A, Borrell M, Galofré J, Grau JM. Alopurinol en el tratamiento de pacientes infectados por el HIV con leishmaniasis visceral. Enferm Infecc Microbiol Clin 1990; 8: 257-258.
119. Scott JAG, Davidson RN, Moody AH, Grant HR, Felmingham DL, Scott GMS et al. Aminosidine (paramomycin) in the treatment of leishmaniasis imported into United Kingdom. Trans R Soc Trop Med Hyg 1992; 86: 617-619.
120. Squires KE, Rosenkaimer F, Sherwood J, Forni AL, Were JBO, Murray HW. Immunochemotherapy for visceral leishmaniasis: a controlled pilot trial of antimony versus antimony plus interferon-gamma.Am J Trop Med Hyg 1993; 48: 666-669.
121. McBride MO, Linney M, Claydon EJ, Weber JN. Visceral leishmaniasis following treatment with liposomal amphotericin B. Clin Infect Dis 1994; 19: 362.
122. Davidson RN, Di Martino L, Gradoni L, Giacchino R, Gaeta GB, Pempinello R et al. Short-course treatment of visceral leishmaniasis with liposomal amphotericin B (AmBisome). Clin Infect Dis 1996; 22: 938-943.
123. Sundar S, Agrawal NK, Sinha PR, Horwith GS, Murray HW. Short-course, low-dose amphotericin B lipid complex therapy for visceral leishmaniasis unresponsive to antimony.Ann Intern Med 1997; 127: 133-137.
124. Thakur CP, Kumar M, Pandey AK. Comparison of regimens of treatment of antimony resistant kala-azar patients: a randomized study. Am J Trop Med Hyg 1991; 45: 435-441.
125. Andreo JA, Vivancos F, Serrano P, Soriano J. Leishmaniasis visceral con respuesta parcial al ketoconazol en un paciente con anticuerpos antivirus de la inmunodeficiencia humana. Med Clin (Barc) 1991; 12; 476-477.
126. Raffi F, Merrien D, Le Pape P, Reliquet V. Use of itraconazole allopurinol combination for the treatment of visceral leishmaniasis in a patients with AIDS. Clin Infect Dis 1995; 21: 1338-1339.
127. Sherwood J, Gachihi GS, Muigai RK, Skillman DR, Mugo M, Rashid JR et al. Phase 2 efficacy trial of an oral 8-aminoquinoline (WR6026) for treatment of visceral leishmaniasis. Clin Infect Dis 1994; 19: 1.034-1.039.
128. Davidson RN, Russo R. Relapse of visceral leishmaniasis in patients who were co-infected with human immunodeficiency virus and who received treatment with liposomal amphotericin B. Clin Infect Dis 1994; 19: 560.
129. Laguna F, Torre-Cisneros J, Moreno V, Villanueva JL, Valencia E. Efficacy of intermittent liposomal amphotericin B in the treatment of visceral leishmaniasis in patients infected with HIV. Clin Infect Dis 1995; 21: 711-712.
130. Matheron S, Cabié A, Parquin F, Mayaud C, Roux P, Antoine M et al. Visceral leishmaniasis and HIV infection: unusual presentation with pleuropulmonary involvement, and effect of secondary prophylaxis. AIDS 1992; 6: 238-240.
131. Pérez-Molina JA, López-Vélez R, Montilla P, Guerrero A. Pentamidine isethionate as secondary prophylaxis againts visceral leishmaniasis in HIV-positive patients. AIDS 1996; 10: 237-238.
132. Ribera E, Ocaña I, Otero J, Cortés E, Gasser I, Pahissa A. Prophylaxis of visceral leishmaniasis in human immunodeficiency virus-infected patients. Am J Med 1996; 100: 496-501.
133. López M, Gil A, Lavilla P, Pintado V, Valencia E, Martínez P et al. Efficacy of liposomal amphotericin B in the treatment and secondary prophylaxis of visceral leishmaniasis in HIV infected patients: report of two cases. J Antimicrob Chemother 1993; 32: 657-659.
134. Gasser RA, Magill AJ, Oster CN, Franke DE, Grögl M, Berman JD. Pancreatitis induced by pentavalent antimonial agents during treatment of leishmaniasis. Clin Infect Dis 1994; 18: 83-90.
135. Antezana G, Zeballos R, Mendoza C, Lyevre PL Valda L, Cárdenas F et al. Electrocardiographic alterations during treatment of mucocutaneous leishmaniasis with meglumine antimoniate and allopurinol. Trans R Soc Trop Med Hyg 1992; 86: 31-33.
136. Veiga JR, Wolff ER, Sampaio RN, Marsden PD. Renal tubular dysfunction in patients with mucocutaneous leishmaniasis treated with pentavalent antimonials. Lancet 1983; 2: 5.693.
137. Van Voorhis WC. Therapy and prophylaxis of systemic protozoan infections. Drugs 1990; 40: 176-202.
138. Seaman J, Boer C, Wilkinson R, Jong J, Wilde E, Sondorp E et al. Liposomal anphotericine B (AmBisome) in the treatment of complicated kala-azar under field conditions. Clin Infect Dis 1995; 21: 188-193.
139. Albrecht H, Stellbrink HJ, Gross G, Berg B, Helmchen U, Mensing H. Treatment of atypical leishmaniasis with interferon-γ resulting in progression of Kaposi's sarcoma in an AIDS patient. Clin Invest 1994; 72: 1.041-1.047.